Recently, Chengdu FANXI Biopharma Co., Ltd., an enterprise in Tianfu Life Science Park, announced that it has completed the A-round financing of tens of millions of RMB.

      This round of financing was led by Zhejiang Hisun Pharmaceutical Co., Ltd. and followed by Chengdu Renyou Investment Co., Ltd. and other companies. This round of financing will be mainly used to promote the clinical study and pre-clinical study of the company's pharmaceutical pipelines for liver disease and tumors.

Chengdu FANXI Biopharma Co., Ltd.

      Founded in March 2017, Chengdu FANXI Biopharma Co., Ltd. is a tech-driven enterprise specializing in innovative drug research and is now settled in Tianfu Life Science Park. Dr. Liu Xiaoyu, the founder of the company, has successively engaged in R&D and management work in well-known pharmaceutical companies such as GlaxoSmithKline, Eli Lilly and Company, and Hisun Pharmaceutical. Professor Yu Niefang, the chief scientist, has been engaged in new drug R&D at Institut Pasteur, S*BIO, a Singaporean company, and Central South University. FANXI focuses on the R&D of original new drugs with independent intellectual property rights in the field of anti-tumor and liver disease, and is committed to becoming an internationally advanced innovative biomedical enterprise to contribute to the health of all mankind.

Zhejiang Hisun Pharmaceutical Co., Ltd.

      Zhejiang Hisun Pharmaceutical Co., Ltd. was founded in 1956 and listed on the A-share market in 2000. In 2012, it established Hisun Pfizer Pharmaceutical Co., Ltd. as a joint venture with Pfizer in the field of branded generic drugs. It has been included in the first batches of "Innovative Enterprises", "National Intellectual Property Demonstration Enterprise" and "National Industrial Brand Cultivation Demonstration Enterprise" and listed in "Top 100 Enterprises in China's Pharmaceutical Industry", "Top 100 Comprehensive Strength of Industrial Enterprises in China's Chemical and Pharmaceutical Industry" and "2017 Top 100 Chinese Pharmaceutical Internationalized Enterprises".

Chengdu Renyou Investment Co., Ltd.

      Chengdu Renyou Investment Co., Ltd. was established in 2016. Its founder has more than 30 years of experience in R&D and operation management in the biomedical industry. Renyou Investment focuses on investing in early biomedical projects, integrating industry-derived investment concepts with market-aligned value assessments. It seeks and nurtures China's top innovative and high-growth entrepreneurial enterprises. Leveraging its industrial resources and integration capabilities, Renyou Investment offers value-added services to its portfolio companies, driving their growth and increasing their overall value.